Akut limfoid leukémia (ALL): vizsgálatok itt: Kína
169 trials · From ClinicalTrials.gov, checked 2026. november 15.. Ask the study team whether a trial fits you.
- 1. fázisTaking peopleStudy for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
- Where
- Hefei, Jinan, Shanghai, Tianjin
- Életkor
- 1 év to 18 év
- People
- 19
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT05495035 - 1. fázisCsak meghívásosA Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies
- Where
- Tianjin
- Életkor
- 3 év to 70 év
- People
- 13
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07784309 - 1. fázisTaking peopleA Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
- Where
- Beijing, Nanchang, Shanghai, Suzhou, Wuhan, Xuzhou
- Életkor
- 3 év to 25 év
- People
- 33
- Run by
- Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
See details and how to joinNCT06927466 - No phaseTaking peopleLow-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
- Where
- Hainan
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
See details and how to joinNCT07763054 - No phaseTaking peoplePediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia
- Where
- Tianjin
- Életkor
- 14 év to 60 év
- People
- 43
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07495631 - No phaseNot yet taking people in KínaPlasma ctDNA Monitoring in Pediatric Acute Leukemia
- Where
- Tianjin
- Életkor
- 3 év to 18 év
- People
- 25
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07751588 - 2/3. fázisTaking peopleNewly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- Where
- Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi’an
- Életkor
- 1 hónap to 18 év
- People
- 1800 worldwide
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06764238 - No phaseTaking peopleChemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
- Where
- Tianjin
- Életkor
- 14 év and over
- People
- 110
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07493161 - Korai 1. fázisTaking peopleA Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
- Where
- Tianjin, Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 28
- Run by
- Grit Biotechnology
See details and how to joinNCT07205315 - 1. fázisTaking peopleKSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
- Where
- Hangzhou
- Életkor
- 18 év to 80 év
- People
- 30
- Run by
- Zhejiang University
See details and how to joinNCT07246707 - Korai 1. fázisNot yet taking people in KínaClinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia
- Where
- Guangzhou
- Életkor
- 3 év to 75 év
- People
- 18
- Run by
- Zhujiang Hospital
See details and how to joinNCT07696481 - 2. fázisTaking peoplePA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
- Where
- Beijing, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Nanjing, Shanghai, Suzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou
- Életkor
- 18 év and over
- People
- 100
- Run by
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07188610 - 1. fázisTaking peopleBlinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL
- Where
- Beijing
- Életkor
- 18 év to 70 év
- People
- 60
- Run by
- Liping Dou
See details and how to joinNCT07677878 - 1/2. fázisTaking peopleExploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia
- Where
- Beijing
- Életkor
- 18 év to 85 év
- People
- 30
- Run by
- Liping Dou
See details and how to joinNCT07575971 - Korai 1. fázisTaking peopleEfficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
- Where
- Suzhou
- Életkor
- 18 év and over
- People
- 20
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07074496 - 1/2. fázisTaking peopleTargeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL
- Where
- Beijing
- Életkor
- 18 év to 85 év
- People
- 20
- Run by
- Liping Dou
See details and how to joinNCT07575919 - 2. fázisNot yet taking people in KínaSHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS
- Where
- Suzhou
- Életkor
- 18 év to 65 év
- People
- 180
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07575412 - 1. fázisNot yet taking people in KínaSingle-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
- Where
- Hefei
- Életkor
- 3 év to 18 év
- People
- 12
- Run by
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07623681 - No phaseTaking peopleABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
- Where
- Tianjin
- Életkor
- 14 év to 60 év
- People
- 92
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07454226 - 1/2. fázisTaking peopleEfficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
- Where
- Shenzhen
- Életkor
- 18 év to 75 év
- People
- 10
- Run by
- Shenzhen University General Hospital
See details and how to joinNCT07584889 - 1/2. fázisTaking peopleTCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
- Where
- Beijing, Changzhi, Tianjin
- Életkor
- 16 év to 70 év
- People
- 30
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT06481735 - 1/2. fázisTaking peopleNanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
- Where
- Beijing
- Életkor
- 3 év to 70 év
- People
- 30
- Run by
- Peking University People's Hospital
See details and how to joinNCT06874946 - 2. fázisTaking peopleFull-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
- Where
- Suzhou
- Életkor
- 15 év to 65 év
- People
- 101
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07564453 - 2. fázisNot yet taking people in KínaSHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS
- Where
- Suzhou
- Életkor
- 15 év to 60 év
- People
- 160
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07562568 - 3. fázisTaking peopleA Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
- Where
- Bengbu, Chengdu, Chongqing, Guangdong, Shanghai, Suzhou, Tianjin, Wuhan, Zhengzhou
- Életkor
- 18 év and over
- People
- 350 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06051409 · EU 2024-511496-14-00